Test 1

Question 1

Tonic-clonic drugs

Answer 1

Phenytoin 
Carbamazepeine
Phenobarbitol
Primidone 
Valpropic Acid

Question 2

Myclonic drugs

Answer 2

Valproic acid

clonazapam

Question 3

Partial drugs

Answer 3

Phenytoin
Carbamazepine
Phenobarbitol
Primidone

Question 4

Absence Drugs

Answer 4

valproic acid

ethosuximide

Question 5

photic-induced

Answer 5

valproic acid

Question 6

Penicillin
MOA:
Clinical uses:
Adverse effects:

Answer 6

MOA: inhibits cell wall synthesis
Clinical uses: skin and soft tissue infections, sinus infection, otitis media
Adverse effects: hypersensitivity reactions and GI disturbances

Question 7

Cephalosporins

Answer 7

MOA: inhibits cell wall synthesis
Clinical uses: skin and soft tissue infection, pneumonia, UTI, meningitis
Adverse effects: hypersensitivity reactions and GI disturbances

Question 8

Carbapenems

Answer 8

MOA: inhibits cell wall synthesis
Clinical uses: intra-abdominal infections, multidrug resistant organisms
Adverse effects: GI upset, seizures

Question 9

Vancomycin

Answer 9

MOA:inhibit bacterial cell wall synthesis by binding to cell precursor
Clinical uses: C. Difficile, skin/soft tissue infections, MRSA, meningitis
Clinical: redman syndrome, nephrotoxicity

Question 10

Aminoglycosides

Answer 10

MOA: inhibits protein synthesis
Agents: gentamicin, tobramycin, amikacin
Clinical: RTI, pneumonia, UTI
Adverse: nephrotoxity, ototoxicity, neurotoxicity

Question 11

Macrolides

Answer 11

MOA: bind to ribosomal subunit inhabituation of protein synthesis
Agents: azithromycin, erythromycin, clarithromycin
Clinical uses: sinusitis, respiratory tract infection
Adverse effects: GI disturbances

Question 12

Tetrocyclines

Answer 12

MOA: inhibits protein synthesis
Agents: Doxycycline, tetracycline, minocycline
Clinical uses: celluitis, RTI, sinusitis, acne vulgaris
Adverse effects: GI disturbances
food interactions, photosensitivity

Question 13

Sulfamethoxazole/trimethroprim (bactrim, septra)

Answer 13

MOA:interferes with bacterial folic acid synthesis
Clinical uses: skin and soft tissue infections, UI, brochitis
Adverse effects: rash, hyperkalemia, GI disturbances, photosensitivity
Considerations: Steven-Johnson syndrome

Question 14

Fluroquinolones

Answer 14

MOA: DNA gyrase inhibitors
Agents: ciprofloxacin, levofloxacin, moxifloxacin
Clinical uses: pneumonia, skin and soft tissue infections, UI, intra-abdominal infection
Black box warning: reports of tendon inflammation and/or rupture w/ quinolone antibiotics; risk may be increased with corticosteroids

Question 15

NRTI

Answer 15

MOA: inhibit activity against HIV-1 reverse transcriptase
Agents: tenofovir, emtricitabine, lamivudine, zidovudine
Adverse effects: GI disturbances, anemia, hyperpigmentation of skin, myalgia
Considerations: preferred backbone of therapy

Question 16

NNRTI

Answer 16

MOA: binds directly to reverse transcriptase & blocks RNA-dependent and DNA dependent
Agents: Efavirenz, Nevirapine, Etrvivine
Adverse effects: neurologic, GI disturbances
Considerations: drug/drug interactions

Question 17

Protease inhibitors (PI)

Answer 17

MOA:prevent formation of mature virions
Adverse effects: headaches, GI disturbance
Considerations: boosted therapy

Question 18

Azoles

Answer 18

MOA: inhibit ergosterol synthesis
Agents: flucoazole, voriconazole
Adverse Effects: neurotoxicity, GI disturbances, increased LFT’s
Considerations: liver function inhibition

Question 19

polyenes

Answer 19

MOA: binds directly to ergosterol leading to cell lysis
Agents: amphotercin preparations
Adverse Effects: nephrotoxicity
Considerations: infusion related interaction and renal toxicity

Question 20

Echinocandins

Answer 20

MOA: Inhibitions of 1->3 beta-glucan synthesis
Agents: micafungin, caspofungin
Adverse Effects: infusion reaction
Considerations: IV only, well tolerated, few drug interaction